Cancer Genetics to Present at “A Future Without Cancer Conference” on Friday, March 17

Published on: Monday, March 13th, 2017 View all Media

RUTHERFORD, N.J., March 13, 2017 — Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that company CEO and President, Panna Sharma will present at “A Future Without Cancer,” a Rodman Premier Series conference being held on Friday, March 17, 2017. The conference will be presented in partnership with Susan G. Komen, and the keynote speaker will be Nancy G. Brinker, former Goodwill Ambassador for Cancer Control to the United Nation’s World Health Organization and founder of Susan G. Komen.

The conference will be bringing together a select group of leading public and private oncology companies on the forefront of eliminating cancer with leading institutional investors, venture capitalists and select industry executives. “The first part of solving cancer is to diagnose and fully understand the disease at the genetic and molecular level,” stated Mr. Sharma. Mr. Sharma continued, “CGI’s genomic and immune-profiling technology, along with our unique portfolio of tests and capabilities, are an important part of helping to understand, eliminate and monitor cancer. We look forward to sharing our insights and our track record of innovation and growth with others at this inaugural conference.”


ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

 

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.